T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 620-626

  Parkhurst, Maria R ^a   Yang, James C ^a   Langan, Russell C ^a   Dudley, Mark E ^a   Nathan, Debbie Ann N ^a   Feldman, Steven A ^a   Davis, Jeremy L ^a   Morgan, Richard A ^a   Merino, Maria J ^a   Sherry, Richard M ^a   Hughes, Marybeth S ^a   Kammula, Udai S ^a   Phan, Giao Q ^a   Lim, Ramona M ^b   Wank, Stephen A ^a   Restifo, Nicholas P ^a   Robbins, Paul F ^a   Laurencot, Carolyn M ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUDESONIDE; CARCINOEMBRYONIC ANTIGEN; MESALAZINE; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; COLITIS; COLONOSCOPY; COLORECTAL CANCER; DIARRHEA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

MURINAE; MUS MUSCULUS;

EID: 79952187823     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.272     Document Type: Article

References (32)

1. Hammarström, S (1999). The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9: 67-81. (Pubitemid 29265523)
2. Hance, KW, Zeytin, HE and Greiner, JW (2005). Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat Res 576: 132-154. (Pubitemid 40982688)
3. Foon, KA, John, WJ, Chakraborty, M, Das, R, Teitelbaum, A, Garrison, J et al. (1999). Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17: 2889-2885.
4. Hörig, H, Lee, DS, Conkright, W, Divito, J, Hasson, H, LaMare, M et al. (2000). Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 costimulatory molecule. Cancer Immunol Immunother 49: 504-514.
5. Marshall, JL, Hoyer, RJ, Toomey, MA, Faraguna, K, Chang, P, Richmond, E et al. (2000). Phase I study in advanced cancer patients of a diversifed prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18: 3964-3973.
6. Smith, CL, Dulphy, N, Salio, M and Cerundolo, V (2002). Immunotherapy of colorectal cancer. Br Med Bull 64: 181-200. (Pubitemid 35238587)
7. Parkhurst, MR, Joo, J, Riley, J P, Yu, Z, Li, Y, Robbins, PF et al. (2009). Characterization of genetically modifed T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 15: 169-180.
8. Robbins, PF, Li, YF, El-Gamil, M, Zhao, Y, Wargo, JA, Zheng, Z et al. (2008). Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specifc T cell functions. J Immunol 180: 6116-6131.
9. Johnson, LA, Morgan, RA, Dudley, ME, Cassard, L, Yang, JC, Hughes, MS et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
10. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
11. Dudley, ME, Yang, JC, Sherry, R, Hughes, MS, Royal, R, Kammula, U et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
12. Warren, EH, Fujii, N, Akatsuka, Y, Chaney, CN, Mito, JK, Loeb, KR et al. (2010). Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specifc for minor histocompatibility antigens. Blood 115: 3869-3878.
13. Klebanoff, CA, Gattinoni, L and Restifo, NP (2006). CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224. (Pubitemid 43882974)
14. Burns, WR, Zheng, Z, Rosenberg, SA and Morgan, RA (2009). Lack of specifc γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114: 2888-2899.
15. Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. (Pubitemid 35231542)
16. Robbins, PF, Dudley, ME, Wunderlich, J, El-Gamil, M, Li, YF, Zhou, J et al. (2004). Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130. (Pubitemid 39628146)
17. Rosenberg, SA and Dudley, ME (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240.
18. Brenner, MK and Heslop, HE (2010). Adoptive T cell therapy of cancer. Curr Opin Immunol 22: 251-257.
19. June, CH, Blazar, BR and Riley, JL (2009). Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-716.
20. Shibata, S, Raubitschek, A, Leong, L, Koczywas, M, Williams, L, Zhan, J et al. (2009). A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res 15: 2935-2941.
21. Zeh, HJ 3rd, Brown, CK, Holtzman, M P, Egorin, MJ, Holleran, JL, Potter, DM et al. (2009). A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 16: 385-394.
22. Blesa, JM and Pulido, EG (2010). Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient. Anticancer Drugs 21 Suppl 1: S23-S26.
23. van Loenen, MM, de Boer, R, Amir, AL, Hagedoorn, RS, Volbeda, GL, Willemze, R et al. (2010). Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA 107: 10972-10977.
24. Bendle, GM, Linnemann, C, Hooijkaas, AI, Bies, L, de Witte, MA, Jorritsma, A et al. (2010). Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16: 565-70, 1p following 570.
25. Cohen, CJ, Zhao, Y, Zheng, Z, Rosenberg, SA and Morgan, RA (2006). Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 66: 8878-8886. (Pubitemid 44449206)
26. Voss, RH, Kuball, J, Engel, R, Guillaume, P, Romero, P, Huber, C et al. (2006). Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specifc TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol Res 34: 67-87. (Pubitemid 43780377)
27. Stanislawski, T, Voss, RH, Lotz, C, Sadovnikova, E, Willemsen, RA, Kuball, J et al. (2001). Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2: 962-970. (Pubitemid 32976170)
28. Rosenberg, SA (2010). Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther 18: 1744-1745.
29. Whiteside, TL (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912.
30. Paulos, CM, Kaiser, A, Wrzesinski, C, Hinrichs, CS, Cassard, L, Boni, A et al. (2007). Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13(18 Pt 1): 5280-5289. (Pubitemid 47510351)
31. Bos, R, van Duikeren, S, Morreau, H, Franken, K, Schumacher, TN, Haanen, JB et al. (2008). Balancing between antitumor effcacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 68: 8446-8455.
32. Zhao, Y, Wang, QJ, Yang, S, Kochenderfer, JN, Zheng, Z, Zhong, X et al. (2009). A herceptin-based chimeric antigen receptor with modifed signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183: 5563-5574.